Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Depreciation & Amortization (CF) (2020 - 2025)

Xeris Biopharma Holdings' Depreciation & Amortization (CF) history spans 6 years, with the latest figure at $335000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) rose 7.03% year-over-year to $335000.0, compared with a TTM value of $1.3 million through Dec 2025, up 7.01%, and an annual FY2025 reading of $1.3 million, up 7.01% over the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $335000.0 at Xeris Biopharma Holdings, down from $338000.0 in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $391000.0 in Q3 2023, with the low at $281000.0 in Q2 2024.
  • Average Depreciation & Amortization (CF) over 5 years is $337750.0, with a median of $336000.0 recorded in 2021.
  • Year-over-year, Depreciation & Amortization (CF) decreased 27.2% in 2024 and then grew 15.66% in 2025.
  • Tracing XERS's Depreciation & Amortization (CF) over 5 years: stood at $349000.0 in 2021, then increased by 4.87% to $366000.0 in 2022, then fell by 5.46% to $346000.0 in 2023, then decreased by 9.54% to $313000.0 in 2024, then increased by 7.03% to $335000.0 in 2025.
  • Per Business Quant, the three most recent readings for XERS's Depreciation & Amortization (CF) are $335000.0 (Q4 2025), $338000.0 (Q3 2025), and $325000.0 (Q2 2025).